366 related articles for article (PubMed ID: 19298583)
1. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
3. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours.
Khan MS; Caplin ME
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S53-74. PubMed ID: 22005115
[TBL] [Abstract][Full Text] [Related]
5. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
6. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
7. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
9. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
13. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
14. [State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies].
Guida T; Belsito Petrizzi V; Fiorentino R; Germano D; Guardasi R; Lentini-Graziano ML; Cartenì G
Minerva Endocrinol; 2001 Dec; 26(4):215-24. PubMed ID: 11782706
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumours.
Alexakis N; Neoptolemos JP
Best Pract Res Clin Gastroenterol; 2008; 22(1):183-205. PubMed ID: 18206821
[TBL] [Abstract][Full Text] [Related]
16. Current medical treatment of pancreatic neuroendocrine tumors.
Yalcin S; Oyan B; Bayraktar Y
Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
18. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors.
Capdevila J; Salazar R; Halperín I; Abad A; Yao JC
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():27-34. PubMed ID: 21311955
[TBL] [Abstract][Full Text] [Related]
19. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
20. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
